Allocation and Distribution of COVID-19 Therapeutics in Ohio



Overview

- EUA granted for Eli Lilly and Company's bamlanivimab Nov 9, 2020
- EUA granted for Regeneron's casirivimab/imdevimab cocktail Nov 21, 2020
- HHS/ASPR oversees allocation and distribution of these drugs in two phases
- Federal monoclonal antibody (mAb) allocation program

Allocations within Ohio

- Leveraged existing process established to allocate and distribute the antiviral drug remdesivir
 - Within each of the state's three hospital zones, allocations to specific hospitals will be determined
- The state has identified a clinically based plan for current and future allotments
 - Consultation with a team of clinicians, pharmacists, public health officials, policymakers, and other health experts
 - Revise allocation strategy based on the evolving situation and modify as needed
- Based on the percentage of COVID-19 patients hospitalized (using seven-day incident data), which is consistent with the federal allocation strategy

Project SPEED

- Federal monoclonal antibody (mAb) allocation program
- Resources provided do not impact state allocations
- Focused on providing mAbs to four priority populations/settings
 - LTC facilities, FQHCs, dialysis centers, and correctional facilities.
- LTC facilities effort being coordinated through the American Society of Consultant Pharmacists
 - 18 long term care pharmacies received first allocations


Options for Medical Directors

- Contact affiliated hospital/healthcare system
- Facility reaches out to LTC Pharmacy
- Facility/physician contacts local home infusion center
- Contact hospital identified on the ASPR/HHS website (TBD)
- Ohio Chapter American Society of Consultant Pharmacist

Therapeutics in Ohio

Website link

Product locator tool now live for states that have opted-in



https://protect-public.hhs.gov/pages/therapeutics-distribution/

Questions?